Pharmaceutical Business review

FDA approves Bristol-Myers biologics manufacturing facility in Devens

The facility employs around 300 scientists, engineers, bioprocess operators, quality specialists and other skilled workers.

Bristol-Myers Squibb Global Manufacturing & Supply president Lou Schmukler said, "The increased manufacturing capacity from the Devens site will support market demand for ORENCIA and positions us well for future production of additional biologic medicines."

The Devens facility received Leadership in Energy and Environmental Design (LEED) Silver certification in 2010.

In December 2009, the laboratory and office building at the facility received LEED Gold certification, the company said.